POTS Adrenergic Ab (CIHR Aims #1&2)

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Calgary
• Treatments: Adrenergic Agents; Isoproterenol; Oxymetazoline; Phenylephrine

Criteria

Inclusion Criteria:

• Patients who have been previously diagnosed with POTS

• Control subjects (patients not diagnosed with POTS)

• Age between 18 - 60 years

• Males and Females (Give that >80% of POTS patients are female, we will attempt to enroll a similar percentage of female control subjects)

• Able and willing to provide consent

Exclusion Criteria:

• Smokers

• Overt cause for postural tachycardia, i.e., acute dehydration

• Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing

• Highly trained athletes

• Subjects with somatization or severe anxiety symptoms will be excluded

• Use of drospirenone (a spironolactone analogue) containing oral contraceptive agent

• Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication

• Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule

• Unable to give informed consent